CDKN2A and melanoma: In 2015, a revision of the prevalence of mutations in susceptibility CMM genes reported that, in 2511 melanoma-prone pedigrees, the mutation prevalence was about 20% for CDKN2A, 0.7% for CDK4, 1% for BAP1, and 0.5% for POT1 [17].